Cargando…

The intracellular signalosome of PD-L1 in cancer cells

Programmed cell death-1 ligand-1 (PD-L1) overexpression in cancer cells accelerates tumor progression. PD-L1 possesses two main pro-oncogenic functions. First, PD-L1 is a strong immunosuppressive molecule that inactivates tumor-specific T cells by binding to the inhibitory receptor PD-1. Second, PD-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Escors, David, Gato-Cañas, María, Zuazo, Miren, Arasanz, Hugo, García-Granda, María Jesus, Vera, Ruth, Kochan, Grazyna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160488/ https://www.ncbi.nlm.nih.gov/pubmed/30275987 http://dx.doi.org/10.1038/s41392-018-0022-9

Ejemplares similares

PD1 signal transduction pathways in T cells
por: Arasanz, Hugo, et al.
Publicado: (2017)

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
por: Zuazo, Miren, et al.
Publicado: (2020)

Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
por: Zuazo, Miren, et al.
Publicado: (2020)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
por: Chocarro de Erauso, Luisa, et al.
Publicado: (2020)

Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies
por: Arasanz, Hugo, et al.
Publicado: (2018)

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
por: Zuazo, Miren, et al.
Publicado: (2019)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer
por: Bocanegra, Ana, et al.
Publicado: (2019)

Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies
por: Hernandez, Carlos, et al.
Publicado: (2020)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
por: Escors, David, et al.
Publicado: (2022)

Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics
por: Arasanz, Hugo, et al.
Publicado: (2020)

Profound Reprogramming towards Stemness in Pancreatic Cancer Cells as Adaptation to AKT Inhibition
por: Arasanz, Hugo, et al.
Publicado: (2020)

Understanding LAG-3 Signaling
por: Chocarro, Luisa, et al.
Publicado: (2021)

Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer
por: Arasanz, Hugo, et al.
Publicado: (2022)

Hyperprogressive Disease: Main Features and Key Controversies
por: Arasanz, Hugo, et al.
Publicado: (2021)

The multi-specific V(H)-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity
por: Edwards, Carolyn J., et al.
Publicado: (2021)

Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer
por: Arasanz, Hugo, et al.
Publicado: (2023)

A core of kinase-regulated interactomes defines the neoplastic MDSC lineage
por: Gato-Cañas, Maria, et al.
Publicado: (2015)

Plasma fractalkine contributes to systemic myeloid diversity and PD‐L1/PD‐1 blockade in lung cancer
por: Bocanegra, Ana, et al.
Publicado: (2023)

A Proteomic Atlas of Lineage and Cancer-Polarized Expression Modules in Myeloid Cells Modeling Immunosuppressive Tumor-Infiltrating Subsets
por: Blanco, Ester, et al.
Publicado: (2021)

Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor
por: Chocarro, Luisa, et al.
Publicado: (2022)

Cutting-Edge CAR Engineering: Beyond T Cells
por: Chocarro, Luisa, et al.
Publicado: (2022)

Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors
por: Blanco, Ester, et al.
Publicado: (2023)

PD-L1, a Master Regulator of Immunity 2.0
por: Kochan, Grazyna
Publicado: (2023)

CAR-T Cells for the Treatment of Lung Cancer
por: Chocarro, Luisa, et al.
Publicado: (2022)

Role of non-classical MHC class I molecules in cancer immunosuppression
por: Kochan, Grazyna, et al.
Publicado: (2013)

Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA Vaccination
por: Echaide, Miriam, et al.
Publicado: (2022)

Cell and Tissue Gene Targeting with Lentiviral Vectors
por: Escors, David, et al.
Publicado: (2012)

PKD phosphorylation and COP9/Signalosome modulate intracellular Spry2 protein stability
por: Martínez, Natalia, et al.
Publicado: (2023)

Clinical landscape of LAG-3-targeted therapy
por: Chocarro, L., et al.
Publicado: (2022)

TNF-α-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy
por: De Ridder, Kirsten, et al.
Publicado: (2022)

A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice
por: Liechtenstein, Therese, et al.
Publicado: (2014)

Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model
por: Merino, María, et al.
Publicado: (2021)

mRNA Vaccines against SARS-CoV-2: Advantages and Caveats
por: Echaide, Miriam, et al.
Publicado: (2023)

Targeting the COP9 signalosome for cancer therapy
por: Du, Wenqi, et al.
Publicado: (2022)

Structural Evolution of TIR-Domain Signalosomes
por: Nimma, Surekha, et al.
Publicado: (2021)

The COP9 signalosome is vital for timely repair of DNA double-strand breaks
por: Meir, Michal, et al.
Publicado: (2015)

Targeted inhibition of the COP9 signalosome for treatment of cancer
por: Schlierf, Anita, et al.
Publicado: (2016)

Conservation of the COP9/signalosome in budding yeast
por: Wee, Susan, et al.
Publicado: (2002)

APC Moonlights to Prevent Wnt Signalosome Assembly
por: McGough, Ian John, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kpcdjlcd368bqt7rejq7f3csej